Table 2 Characteristics of PLWH participants by low and high phenotypic age acceleration (PAA)
HIV-related parameters (n = 333) | Low PAA (N = 160) | High PAA (N = 173) | P-value |
|---|---|---|---|
Mode of HIV acquisition | 0.92 | ||
 Heterosexual | 119 (74%) | 126 (73%) | |
 Homosexual | 18 (11%) | 24 (14%) | |
 Injecting drug use | 1 (1%) | 1 (1%) | |
 Other | 3 (2%) | 2 (1%) | |
 Unknown | 19 (12%) | 20 (11%) | |
Nadir CD4 count (cells/mm3) | 178 (88–257) | 175 (92–242) | 0.64 |
Current CD4 count (cells/mm3) | 664 (511–819) | 596 (441–769) | 0.024 |
Current CD8 count (cells/mm3) | 656 (516–846) | 726 (517–950) | 0.18 |
Nadir CD8 count (cells/mm3) | 428 (301–554) | 435 (298–646) | 0.37 |
Current CD4:CD8 ratio | 1.00 (0.74–1.33) | 0.88 (0.63–1.22) | 0.028 |
Baseline HIV-1 RNA (log10 copies/mL) | n = 114 | n = 103 | 0.18 |
4.74 (4.33–5.24) n = 114 | 4.69(4.13–5.11) n = 103 | ||
Current undetectable HIV-1 RNA (< 50 copies/mL) | 157 (98%) | 168 (97%) | 0.73 |
CDC staging at baseline | 0.75 | ||
 A | 74 (46%) | 73 (42%) | |
 B | 62 (38%) | 73 (42%) | |
 C | 24 (15%) | 27 (16%) | |
CDC staging at current | 0.83 | ||
 A | 63 (40%) | 63 (37%) | |
 B | 70 (44%) | 81 (47%) | |
 C | 25 (16%) | 28 (16%) | |
Duration of ART (years) | 16 (12–19) | 16 (14–19) | 0.35 |
Duration of HIV (years) | 18 (15–21) | 19 (16–21) | 0.23 |
Current ART regimen | 0.048 | ||
 NNRTI | 102 (64%) | 83 (48%) |  |
 PI | 38 (24%) | 63 (36%) |  |
 NNRTI+PI | 10 (6%) | 11 (6%) |  |
 INSTI | 2 (1%) | 5 (3%) |  |
 Other | 8 (5%) | 11 (6%) |  |
VACS index score | 22 (12–28) | 22 (18–34) | 0.012 |